StreetAlpha
13F holdings · Q3 2026

Trails Edge Capital Partners

Atlanta, GA · files as Trails Edge Capital Partners, LP
Know the moment Trails Edge Capital Partners filesYou follow Trails Edge Capital Partners An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 2077247

Trails Edge Capital Partners reported 38 stocks worth $696M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are LBRX (6.3%), BMRN (5.8%) and NRIX (5.4%). Compared with Q2 2026, the fund opened new positions in OBX, TNGX and CLDX, added to BMRN, DSGN and CYTK, trimmed LBRX, TRAX and XENE and sold out of MIRM, INSM and SNDX.

Latest filing: what Trails Edge Capital Partners did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
9 new12 added7 trimmed6 sold outBought about $252M · sold about $165M
New 9
See all 9 →
Added 12
See all 12 →
Trimmed 7
See all 7 →
Sold out 6
See all 6 →

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$696M+10.5% vs last quarter
Stocks held389 new · 6 sold out
Top 5 weight27.0%spread out
Turnover60%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 4 qtrsHeld
1
LBRX
LB Pharmaceuticals Inc
$44.1M6.3%1.1M−374K (−25%)4 of 4
2
BMRN
Biomarin Pharmaceutical Inc
$40M5.8%667K+155K (+30%)2 of 4
3
NRIX
Nurix Therapeutics Inc
$37.3M5.4%1.6MNo change4 of 4
4
OBX
Obsidian Therapeutics Inc
$34.3M4.9%2.5MNew position1 of 4
5
IMCR
Immunocore Hldgs PLC
$32.2M4.6%1.1MNo change4 of 4
6
FDMT
4D Molecular Therapeutics in
$31.9M4.6%2.2MNo change3 of 4
7
DSGN
Design Therapeutics Inc
$31.4M4.5%2.5M+499K (+25%)3 of 4
8
CYTK
Cytokinetics Inc
$31M4.5%470K+182K (+63%)3 of 4
9
TRAX
First Tracks Biotherapeutics
$28.8M4.2%814K−700K (−46%)2 of 4
10
FTH
Sensei Biotherapeutics Inc
$28M4.0%942K+426K (+83%)3 of 4
🔒 28 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
MIRM
Mirum Pharmaceuticals Inc
$26.1M223K
INSM
Insmed Inc
$24.6M230K
SNDX
Syndax Pharmaceuticals Inc
$24.3M1.1M
RVMD
Revolution Medicines Inc
$21.7M116K
INCY
Incyte Corp
$17.6M155K

🔒 Free account: see all 6.

Reported value

last 4 quarters
$405MQ4 '25
$425MQ1 '26
$630MQ2 '26
$696MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Trails Edge Capital Partners 13F FAQ

What does Trails Edge Capital Partners own?

Trails Edge Capital Partners reported 38 stocks worth $696M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are LBRX (6.3%), BMRN (5.8%) and NRIX (5.4%). The table above lists every position in the filing (the top 10 without an account).

What did Trails Edge Capital Partners buy and sell in Q3 2026?

Compared with Q2 2026: 9 new positions, 12 added to, 7 trimmed and 6 sold out. New positions include OBX, TNGX and CLDX. It sold all of MIRM, INSM and SNDX.

When will Trails Edge Capital Partners file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Trails Edge Capital Partners's portfolio worth?

The Q3 2026 filing reports $696M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.